These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 36136896)

  • 1. In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay.
    Fumagalli C; Betella I; Ranghiero A; Guerini-Rocco E; Bonaldo G; Rappa A; Vacirca D; Colombo N; Barberis M
    Pathologica; 2022 Aug; 114(4):288-294. PubMed ID: 36136896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical assays for assessment of homologous recombination DNA repair deficiency.
    Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF
    Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homologous recombination deficiency real-time clinical assays, ready or not?
    Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
    Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concordance between Three Homologous Recombination Deficiency (HRD) Assays in Patients with High-Grade Epithelial Ovarian Cancer.
    Fountzilas E; Papadopoulou K; Chatzikonstantinou T; Karakatsoulis G; Constantoulakis P; Tsantikidi A; Tsaousis G; Karageorgopoulou S; Koumarianou A; Mauri D; Ntavatzikos A; Saridaki Z; Petrakis G; Fostira F; Fountzilas G; Liontos M
    Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency-Associated Genomic Instability in Ovarian Cancer.
    Pfarr N; von Schwarzenberg K; Zocholl D; Merkelbach-Bruse S; Siemanowski J; Mayr EM; Herold S; Kleo K; Heukamp LC; Willing EM; Menzel M; Lehmann U; Bartels S; Chakraborty S; Baretton G; Demes MC; Döring C; Kazdal D; Budczies J; Rad R; Wild P; Christinat Y; McKee T; Schirmacher P; Horst D; Büttner R; Stenzinger A; Sehouli J; Vollbrecht C; Hummel M; Braicu EI; Weichert W;
    JCO Precis Oncol; 2024 Mar; 8():e2300348. PubMed ID: 38513168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study.
    Pepe F; Guerini-Rocco E; Fassan M; Fusco N; Vacirca D; Ranghiero A; Venetis K; Rappa A; Taormina SV; Russo G; Rebellato E; Munari G; Moreno-Manuel A; De Angelis C; Zamagni C; Valabrega G; Malapelle U; Troncone G; Barberis M; Iaccarino A
    J Clin Pathol; 2024 Jun; 77(7):478-485. PubMed ID: 37072171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer.
    Wehn AK; Qiu P; Lunceford J; Yarunin A; Cristescu R; Liu L; Roessler K; Bilke S; Day JR; Timms KM; Weichert W; Marton MJ
    Gynecol Oncol; 2024 May; 184():67-73. PubMed ID: 38290412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial.
    Roma C; Esposito Abate R; Sacco A; Califano D; Arenare L; Bergantino F; Pisano C; Cecere SC; Scambia G; Lorusso D; Artioli G; Tasca G; Spina A; Russo D; Gadducci A; De Angelis C; Bologna A; Marchini S; Capoluongo ED; Perrone F; Pignata S; Normanno N
    Eur J Cancer; 2024 Jul; 206():114127. PubMed ID: 38797038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer Diagnosis.
    Guarischi-Sousa R; Kroll JE; Bonaldi A; Pierry PM; Villela D; Souza CA; Silva JS; Bürger MC; Oliveira FA; de Paula MG; Meliso FM; de Almeida LG; Monfredini PM; de Oliveira AG; Milanezi F; Scapulatempo-Neto C; Yamamoto GL
    Diagnostics (Basel); 2023 Oct; 13(21):. PubMed ID: 37958189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis.
    Batalini F; DaSilva LL; Campoverde L; Comini ACM; Carvalho BM; Nogueira W; Silveira H; Ernst BJ; Mina LA
    Chin Clin Oncol; 2023 Jun; 12(3):21. PubMed ID: 37211773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.
    Pujade-Lauraine E; Brown J; Barnicle A; Wessen J; Lao-Sirieix P; Criscione SW; du Bois A; Lorusso D; Romero I; Petru E; Yoshida H; Vergote I; Colombo N; Hietanen S; Provansal M; Schmalfeldt B; Pignata S; Martín Lorente C; Berton D; Runnebaum IB; Ray-Coquard I
    JCO Precis Oncol; 2023 Jan; 7():e2200258. PubMed ID: 36716415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?
    Ngoi NYL; Tan DSP
    ESMO Open; 2021 Jun; 6(3):100144. PubMed ID: 34015643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic Analysis of Homologous Recombination Deficiency Testing in Ovarian Cancer-Development of Recommendations for Optimal Assay Performance.
    Romey M; Rodepeter F; Hattesohl A; Kaiser K; Teply-Szymanski J; Heitz F; Staebler A; Serra V; Grass A; Marmé F; Timms KM; Harter P; Llop-Guevara A; Kommoss S; Boekhoff J; Denkert C
    Mod Pathol; 2024 Apr; 37(4):100445. PubMed ID: 38341130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homologous Recombination Deficiency as an Ovarian Cancer Biomarker in a Real-World Cohort: Validation of Decentralized Genomic Profiling.
    Denkert C; Romey M; Swedlund B; Hattesohl A; Teply-Szymanski J; Kommoss S; Kaiser K; Staebler A; du Bois A; Grass A; Knappmeyer C; Heitz F; Solimeno C; Ebel T; Harter P; Marmé F; Jank P; Gaiser T; Neff C; Wagner U; Timms KM; Rodepeter F
    J Mol Diagn; 2022 Dec; 24(12):1254-1263. PubMed ID: 36191839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can!
    Magliacane G; Brunetto E; Calzavara S; Bergamini A; Pipitone GB; Marra G; Redegalli M; Grassini G; Rabaiotti E; Taccagni G; Pecciarini L; Carrera P; Mangili G; Doglioni C; Cangi MG
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer.
    Wen H; Feng Z; Ma Y; Liu R; Ou Q; Guo Q; Shen Y; Wu X; Shao Y; Bao H; Wu X
    BMC Cancer; 2022 May; 22(1):550. PubMed ID: 35578198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Relevance of BRCA1 Promoter Methylation Testing in Patients with Ovarian Cancer.
    Blanc-Durand F; Tang R; Pommier M; Nashvi M; Cotteret S; Genestie C; Le Formal A; Pautier P; Michels J; Kfoury M; Hervé R; Mengue S; Wafo E; Elies A; Miailhe G; Uzan J; Rouleau E; Leary A
    Clin Cancer Res; 2023 Aug; 29(16):3124-3129. PubMed ID: 37067532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With?
    Kekeeva T; Andreeva Y; Tanas A; Kalinkin A; Khokhlova S; Tikhomirova T; Tyulyandina A; Popov A; Kuzmenko M; Volkonsky M; Chernorubashkina N; Saevets V; Dmitriev V; Nechushkina V; Vedrova O; Andreev S; Kutsev S; Strelnikov V
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.
    Morgan RD; Clamp AR; Barnes BM; Timms K; Schlecht H; Yarram-Smith L; Wallis Y; Valganon-Petrizan M; MacMahon S; White R; Morgan S; McKenna S; Hudson E; Tookman L; George A; Manchanda R; Sundar SS; Nicum S; Brenton JD; Kristeleit RS; Banerjee S; McNeish IA; Ledermann JA; Taylor SS; Evans DGR; Jayson GC
    Int J Gynecol Cancer; 2023 Aug; 33(8):1253-1259. PubMed ID: 37072323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homologous recombination deficiency and ovarian cancer.
    Ledermann JA; Drew Y; Kristeleit RS
    Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.